ARTV
NASDAQArtiva Biotherapeutics Inc.
Price$5.92-3.11 (-34.40%)
2026-07-162026-10-16
News · 26 weeks90-74%
2026-04-192026-10-11
Mix5590d
- Insider37(67%)
- Other10(18%)
- SEC Filings8(15%)
Latest news
25 items- INSIDERSEC Form 4 filed by Artiva Biotherapeutics Inc.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Artiva Biotherapeutics Inc.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Artiva Biotherapeutics Inc.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Artiva Biotherapeutics Inc.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Artiva Biotherapeutics Inc.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- PRArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-upPoster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseasesPoster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at least
- PRArtiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren diseaseMean stimulated salivary flow increased from 0.4 to 1.1 mL/min among eight patients with baseline hyposalivation and available six-month dataUpdated safety data across 73 Phase 2a basket study patients support the potential for outpatient administration, with no cytokine release syndrome, ICANS or treatment discontinuations due to adverse events SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a cli
- PRArtiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s DiseaseSAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire de Paris: Abstract Title:AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined withRituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren DiseasePresenting Au
- PRArtiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation ForumSAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days. A
- INSIDERChief Executive Officer Aslan Fred was granted 110,000 shares, increasing direct ownership by 7% to 1,604,765 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Executive Officer Aslan Fred was granted 45,000 shares, increasing direct ownership by 3% to 1,494,765 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Director Stoppel Laura4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Director Hougen Elizabeth L4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Director Sorg Elaine K.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Director Daniels Brian4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Director Baker Daniel G.4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERSEC Form 4 filed by Director Moore Alison4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERPresident & Head of R&D Miralles Gines Diego was granted 45,000 shares, increasing direct ownership by 58% to 122,500 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Tech Operations Officer Horan Christopher was granted 40,000 shares, increasing direct ownership by 14% to 323,084 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERCOO, CLO, Compliance Officer Bush Jennifer was granted 45,000 shares, increasing direct ownership by 14% to 374,529 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Medical Officer Banerjee Subhashis was granted 30,000 shares, increasing direct ownership by 21% to 170,947 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECSEC Form S-8 filed by Artiva Biotherapeutics Inc.S-8 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- SECArtiva Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- INSIDERChief Executive Officer Aslan Fred sold $255,746 worth of shares (23,429 units at $10.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,449,765 units (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
ARTV FAQ
6 questionsWhere does ARTV stock trade?
Artiva Biotherapeutics Inc. (ARTV) is listed on NASDAQ.What sector and industry is ARTV in?
Artiva Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Artiva Biotherapeutics Inc. go public?
Artiva Biotherapeutics Inc. (ARTV) completed its IPO in 2024.What are analysts saying about ARTV?
Artiva Biotherapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-06-11. Recent price targets range from $1200.00 to $2300.00.What companies are similar to ARTV?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ARTV side-by-side with any of them on Quantisnow.How can I track ARTV on Quantisnow?
Quantisnow aggregates Artiva Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARTV to receive live email and push alerts on every new disclosure.